Preclinical murine tumor models of mammary carcinoma have demonstrated tumor regression with aOX40 + aPD‐1 dual treatment, with efficacy likely dependent on augmentation to CD4+ T‐cell helper functions, enhancing CD8+ T‐cell cross‐priming and recruitment to TDLNs.50 Here, CD8A is linked to neoplasm.